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ABSTRACT 
EFFECT OF TABLET COMPRESSION ON THE DISSOLUTION OF 
ASPIRINTABLETS USING A NOVEL OFF-CENTER PADDLE IMPELLER 
(OPI) DISSOLUTION TESTING SYSTEM 
 
by 
Chuan Sun 
In the pharmaceutical industry, dissolution testing is routinely carried out to determine 
the dissolution rate of oral solid dosage forms. Among several testing devices, the 
USP Dissolution Apparatus 2 is the device most commonly used.  However, despite 
its widespread use, this apparatus has been shown to produce test failures and to be 
very sensitive to a number of small geometry changes. 
The objective of this study was to determine whether a novel dissolution 
system termed “OPI” for “off-center paddle impeller” was sensitive enough to 
determine differences in tablet dissolution profiles caused by different compression 
pressure during the tablet manufacturing process.  The OPI Dissolution System simply 
consists of a modified Apparatus 2 in which the impeller is placed 8mm off center in 
the vessel.   
In this work, aspirin tablets were manufactured from powder with a manual 
tablet press using three different compression pressures.  The dissolution profiles of 
these tablets were then obtained in both the OPI system and the standard USP 
Apparatus 2 system.  Tests were conducted by dropping the tablets in the vessels at 
the beginning of an experiment, and, in separate experiments, by initially 
immobilizing the tablets on the vessel bottom at nine different locations.  This 
approach has been used in the past by our group to determine the sensitivity of the 
dissolution apparatus to minor changes in the geometry of the dissolution system. 
All dissolution profiles were found to be affected by the compression pressure.  
Faster dissolution profiles were obtained at lower compression pressures.  When 
tablets were dropped in the vessel, a comparison of the dissolution profiles obtained in 
the standard Apparatus 2 system and in the OPI system showed that similarly 
manufactured tablets produced statistically similar dissolution profiles in both 
systems, i.e., that the OPI system was just as sensitive as the standard system to 
variations in the tablet manufacturing process.  However, when the tablets were 
immobilized during the dissolution process, the standard system generated very 
different dissolution profiles even for tablets manufactured at the same compression 
pressure.  By contrast, the dissolution profiles in the OPI system for tablets 
manufactured at different pressure but located at different positions were very similar. 
It can be concluded that the OPI system is sensitive enough to detect 
differences in intrinsic tablet dissolution rates (such as those caused, as in this case, by 
changes in the manufacturing process), while being unaffected by small changes in the 
system geometry that instead caused the standard system to fail.  Therefore, the OPI 
system appears to be a more reliable dissolution testing apparatus than the current 
apparatus. 
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CHAPTER 1 
INTRODUCTION 
 
Dissolution is a process by which the drug substance in a formulation dissolves into 
solution. Solid dosage forms such as tablets are the most common used method to 
administer drugs. Therefore, dissolution testing is widely used in the pharmaceutical 
industry to determine the dissolution rate of solid dosage forms. The dissolution testing is 
a critical tool in the process of drug discovery that measuring the stability of the solid 
dosage product. Also it‟s an overriding method determining solid dosage drug in-vivo 
availability. Thus this Dissolution testing is an essential requirement for the development, 
establishment of in vitro dissolution and in vivo performance (IVIVR), registration and 
quality control of different dosage forms. 
Although the USP lists several different dissolutiontest apparatuses,most dissolution 
testsare currently conducted with USP DissolutionTest Apparatuses 1 and 2. The USP 
DissolutionTest Apparatus 2 is the most commonly andwidely used apparatus specified 
by the USP. The dimensions, characteristics,and operating conditions of USP 
DissolutionTest Apparatus 2 are detailed by the USP, 
1
and all users must conform to these 
prescriptionswhen conducting dissolution tests.The USP Dissolution Test Apparatus 
2comprises a glass vessel and an agitation system.The glass vessel is a cylindrical glass 
tank with asemispherical bottom, and a working volume of900 mL. The agitation system 
consists ofa two-blade paddle impeller mounted on a shaftcentrally located in the vessel 
and profiled to followthe hemispherical portion of the vessel. In theindustrial practice, 
replicate dissolution tests aretypically conducted in parallel using commerciallyavailable 
systems containing six or more individualUSP Dissolution Test Apparatus 2 units. These 
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systemsallow the agitation system(motor and impellers) to be lifted above the 
rackholding the vessels, as shown in this figure, inorder to prepare the system for the 
actual test.Each vessel is filled with a prescribed amount of afluid simulating gastric or 
intestinal fluids, andmaintained at constant temperature of 37℃byeither a water bath or a 
heating jacket. 
The USP Dissolution Test Apparatus 2 hasbeen used in the pharmaceutical industry 
fordecades, since this test was first officiallyintroduced many years ago.
2
 
Nevertheless,the hydrodynamics of USP Apparatus 2 vessel hasbeen reported to play a 
major role in the poor reproducibilityof dissolution testing data and the inconsistencyof 
dissolution results.
17–19
And despite its widespread use in the industry,dissolution testing 
remains susceptible to significanterror and test failures. A review of theliterature shows 
that there have been numerousreports describing high variability of testresults,
3-10
 even 
when the so called „„calibratortablets‟‟ (i.e., tablets manufactured for the solepurpose of 
testing the proper operation of thedissolution test equipment) are used.
4,6,9,11,12
Failures 
linked to dissolution testing resulted inover forty product recalls during the period 2000–
2002,representing 16% of non-manufacturing recalls fororal solid dosage forms. 
Irrespective of theunderlying causes (such as incorrect use of theequipment or deviation 
of dissolution profile fromthe standard caused by incorrect tablet formulation)failed 
dissolution tests can result in productrecalls, costly investigations, potential 
productiondelays, which, in turn, can have a significantlynegative financial impact 
because standard system isstrongly affectedby even small variations in the geometry of 
theapparatus.
13-15
 
In previous experiments16-18, data have shown that OPI System is very reliable. 
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Due to the fact that OPI system has faster dissolution rate of the tablet and was 
respectively independent to the tablets locations on the bottom of the vessel, we can see 
OPI System is more robust and more effective than the Standard System in the 
dissolution test. However, whether new system is sensitive enough to detect the slice 
difference between tablets is worth to discuss.   
The main objective of this study was to verify the sensibility of the OPI system 
regarding tablets compression pressure difference. To do so, twodifferent methodologies 
were used in this study. Efforts were made to eliminate any other factors that could also 
affectthe test results in order to analyze solely tablets compression differences andits 
effect on thedissolution profiles in both Standard system and OPI system.  
In addition,as shown in previous study on the USP Dissolution Apparatus 2 (Bai 
etal., 2007), the exact location of the dissolving tablet introduces significant variations 
inthe flow and in the shear stress experienced by the tablet, which, in turn, can affect 
thedissolution process and the dissolution profiles. In order to confirm the reliability of 
the OPI system, dissolution testswere conducted in USP Dissolution Testing Apparatus 
2and in OPI system using tablets with different compression pressure at 9 different 
locations at the bottom of the USP Apparatus 2dissolution vessel, i.e., with tablets located 
10° or 20° off-center and at different positions. Statistical tools were then used to 
evaluate and compare theresults of dissolution profiles in standard system and in OPI 
system. 
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CHAPTER 2 
EXPERIMENTAL APPARATUS, MATERIALS, AND METHOD 
 
2.1 Dissolution Apparatuses 
 
In this work, two dissolution testing apparatus systems were used. A standard USP 
Dissolution TestingApparatus 2 (hereafter called the “Standard System”)and a modified 
system, which, in this work, isreferred to as “OPI system” for “off-center paddle 
impeller”system. 
The Standard System consisted of a Distek 5100bathless dissolution apparatus 
shown in Figure 2.1(Distek Inc., North Brunswick, New Jersey).Seven dissolution 
vessels can be operated at a time. EachUSP Apparatus 2 vessel used as the dissolution 
vesselconsisted of an unbaffled, cylindrical, transparentglass tank with a hemispherical 
bottom, an internaldiameter, T, of 100.16mm, and an overall capacityof 1L. When the 
vessel was filled with 500mLof dissolution media, the corresponding liquid height,H, as 
measured from the bottom of the vessel, was78.6mm. 
The impeller consisted of a two-blade paddle impeller connected to the 
Disteksystem (Distek Inc.) motor with the steel shaft. The exact geometry of each 
componentofthe impeller was: shaft diameter, 9.53mm; length of thetop edge of the blade, 
74.10mm; length of the bottomedge of the blade, 42.00mm; height of the blade, 19.00mm; 
thickness of the blade, 5.00mm. The distancebetween the lower edge of the impeller 
bladeand the vessel‟s inside bottom was 25mm. These dimensions were obtained 
bymeasuring themwith a caliper. Figure 3a shows the standardUSP Dissolution Testing 
Apparatus 2. 
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The OPI system was a modification of the standard system(Figure 2.2)in which 
the impeller which wasplaced 8mm off center with respect to the vessel 
centerline(Figure2.3). To make this change, one of the plastic spring inserts mounted on 
the metal plate ofthe Distek dissolution equipment (Distek Inc.), which ensuresthat the 
vessel locates at the centerline (Figure2.4), was removed. After removing this plastic 
spring insert, the vessel was shifted with respect to the paddle shaft by an exactly 8mm, 
thusresulting in an off-centered impeller with respect tothe vessel.The clearance from the 
bottom to the paddle end is 25mm, that is, the same as inthe Standard System. Figure 2.3 
shows the OPI dissolutiontesting system. 
 
 (a) (b) 
Figure 2.1USPdissolution testing System:(a) Distek 5100 bathless dissolution 
apparatus,(b) USP dissolution testingapparatus 2: paddle impeller andglass vessel. 
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Figure 2.4Modification of the standard system to obtainthe OPI system: (a) vessel in the 
standard system, (b) plasticspring inserts exposed after removing the vessel in 
thestandard system, (c) system after one of the plastic springinserts has been removed, 
and (d) system after the vesselwas repositioned to obtain the OPI system. 
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2.2 Experimental Materials 
 
Four types of aspirin tablets were tested in this work, i.e., commercial 360mgwhite, round 
shaped uncoated aspirin tablets (Item Code: NDC:59779-249; Active Ingredient: Aspirin 
(325 mg); Inactive Ingredient: Starch) with diameter of 11 mm, purchased from CVS 
Pharmacy, as well as three other types of tablets obtained by grinding and reconstituting 
tablets using different compression tablets.In order to make these tablets, 100 tablets were 
well ground to a fine powder using a mortar(Figure 2.6b) and pestle for ten minutes.  The 
resulting powder was apportioned in 360-mg doses (the mass of each was measured with 
an analytical balance).  The average tablet mass was measured to be 360±5 mg.  Each 
dose was then poured in a die and the die was placed in a press (Carver Laboratory Press, 
Fred S. Carver Inc.; Model C; Figure 2.5).  The powder was manually compressed at the 
desired compression pressure.  Three compression pressures were used here i.e., 1000 
lb/0.12in
2
, (here referred to as “1000 pound”), 2000 lb/0.12in2 (“2000 pound”), and 3000 
lb/0.12in
2
 (“3000 pound”)(Figure 2.6a), respectively.The compression pressurewas 
determined with the pressure gauge connected to the press. All the tablets needed in all 
the experiments were manufactured in one single batch to insure the uniformity of the 
compressed tablets at each pressure.  The resulting tablets consisted of cylindrical disks, 1 
cm in diameter and approximately 2-3 mm thick (the actual thickness depended on the 
compression pressure). 
The dissolution medium for the aspirintablets consisted of a0.05 M acetate buffer 
to which glacial acetic acid wasadded to reach a final pH value of 4.5±0.05. This 
mediumwas deaerated according to the degassing methoddeveloped by Moore following 
the USP GeneralTest Chapter on Dissolution. Accordingly, themedium was placed in a 
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carboy tank, which was thenconnected to a vacuum pump. Vacuum was appliedfor 30min, 
whereas all other valves in the systemwere closed. This stock solution was used as 
needed(typically in 500mL aliquots per experiment). 
 
Figure 2.5  Carverlaboratory press model C. 
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 (a) (b) 
Figure 2.6(a) From left to right: Commercial tablets, 1000-pound tablets, 2000-pound 
tablets, 3000-pound tablets; (b)Mortar used for manufacturing powder. 
 
 
2.3 Experimental Method 
 
Two testing methods were used here to conduct dissolution tests, as follows.   
 Testing Method #1: the tablet was dropped in the dissolution medium at the 
beginning of the experiment (USP Method); 
 Testing Method #2: the tablet was fixed in place at one of nine different tablet 
positions at the bottom the vessel (i.e., 0°, 10°, 20°) prior to the addition of the 
dissolution medium as specified below. 
When Testing Method #1 was used, a prescribed volume (500 mL) of the appropriately 
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deaerated dissolution medium, previously preheated at 37◦C, was gently poured into the 
vessel in order to minimize the introduction of gas.  Because of the thermal inertia of the 
vessel, the resulting temperature of the liquid was 37◦C. This temperature was maintained 
throughout the dissolution experiment by the system‟s temperature controller.  Then a 
tablet was dropped in the Standard System vessel and another in the OPI System vessel, 
agitation was started, and a first set of samples was manually removed as described 
below.  The agitation speed was 50 rpm for the aspirin dissolution tests in Standard 
System, and 36 rpm in the OPI System, as specified in previous work by this group.  This 
agitation value had been previous identified as the agitation speed at which the OPI 
system would generate the same dissolution profile as a standard system stirred at 50 rpm 
when a tablet was located at the central position (as better described below). 
The time interval between samples was 5 min for the first 30 min, and every 15 
min from 30 min to 60 min. Each experiment lasted 60 min, and a total of 8 samples were 
taken for each experiment. All experiments were performed in triplicates. 
When Testing Method #2 was used, the tablet was glued in place prior to the 
addition of the dissolution medium at the beginning of the experiment in order to 
determine the sensitivity of the dissolution system to tablet location during a typical 
dissolution experiment. Accordingly, a tablet was attached at one of several predefined 
locations at the vessel‟s bottom with a very small bead of a commercial acrylic glue prior 
to each experiment.  Three tablet positions were studied in the Standard System, that is, 
the tablet was centered in the vessel, placed 10o off center, or placed 20
o
 off center 
(Figure 2.5). This angle originated from the center of the sphere comprising the 
hemispherical vessel bottom and was measured starting from the vertical centerline to the 
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point of interest, (e.g., the angle would be zero for the central point below the impeller). 
As for the OPI system, nine positions at the vessel‟s bottom were selected, as 
shown in Figure 2.6. Position O in this figure represents the center of the vessel bottom. 
Positions A1–D1 were all 10º off center from the vessel‟s vertical centerline (Figure 2.6). 
Positions A1–D1 were all on the same inner circle and were spaced 90º apart from each 
other. Positions A2–D2 were 20º off center from the vessel‟s vertical centerline (Figure 
2.6). The vertical centerline through the impeller intersected the vessel‟s bottom between 
Position 1 and Position 3, some 8mm away from the vessel‟s bottom. 
The vessel with the attached tablet was placed in the Distek apparatus, and then 
the appropriate medium volume (500 mL based on USP dissolution test for aspirin) of 
deaerated dissolution medium, previously preheated at 37.5◦C, was gently poured into the 
vessel in order to minimize the introduction of gas and prevent rapid initial dissolution of 
the tablet.  Again, because of the thermal inertia of the vessel, the resulting temperature 
of the liquid was 37◦C. This temperature was maintained throughout the dissolution 
experiment by the system‟s temperature controller. Because of the potential sensitivity of 
the process to the initial tablet dissolution caused by liquid addition, extreme care was 
taken to ensure that this procedure was consistent and reproducible and that it did not 
result in any liquid splashing. The agitation was started immediately after the addition of 
the dissolution medium.  Sampling was conducted with the same time frequency as 
specified above. 
Sampling consisted of removing a 10 mL medium aliquot with a 10-mL syringe 
connected to a cannula (2 mm internal diameter). The volume of medium removed by 
sampling was not replaced, in accordance with the USP procedure (USP, 2012). The 
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sampling point was horizontally located midway between the impeller shaft and the 
vessel wall, and midway between the top edge of the impeller and the surface of the 
dissolution medium, that is, within the sampling zone prescribed by USP. After the 
sample withdrawal, about 2 mL of the sample was discarded, the cannula was removed, 
and a polyvinylidene fluoride (PVDF) 0.45-m filter was mounted on the syringe. The 
remaining sample volume (about 8 mL) was transferred to a vial until analyzed. 
Analysis of samples was carried out using 1-cm quartz cells placed in an 
ultraviolet (UV)–visible spectrophotometer (Varian Cary 50 Bio, Varian, Inc., Palo Alto, 
CA) measuring absorbance at specified wavelengths, that is, 265nm for aspirin.  
Beforeputting the quartz cell into the UV spectrometer, the cell was rinsed three times 
with the same solution sample. 
A calibration curve was obtained bypreparing reference standard solutions of 
aspirin tablets with known concentrations to obtain solutions of differentknown 
concentrations. In order to obtain a calibration curve, pure aspirin (A2093 Sigma-Aldrich) 
was used. The absorbance of these solutionswas obtained in order to generate an 
absorbanceversus concentration standard curve. The calibrationcurves were linear 
(R
2
=0.9999 for aspirin) in the concentrationranges of interest here. 
Thecalibration data and calibration curve for aspirinusing the UV 
spectrophotometer to determine the sample absorbance at the wavelength 265nm are 
presented in Table 2.2 and Figure 2.6, respectively.  These results showed that the 
calibration curve was linear (R
2
=0.9999) in the concentration range of interest here. 
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Table 2.1Operating Conditions for Dissolution Experiments 
Medium 500 mL, 0.05 M acetate buffer, pH of 
4.50 ±0.05 
Temperature 37.5
o
C 
Agitation Speed for Standard System 50 rpm 
Agitation Speed for OPI System 36 rpm  
Filter  
UV Wavelength (UV Spectroscopy) 265 nm 
Standard Tablets CVS Uncoated Aspirin Tablets 
Compressed Tablets CVS Uncoated Aspirin Tablets obtained 
at pressure of 1000, 2000, 3000 lb/in
2
 
Time 5-min interval; 60 min total 
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OA1A2 C1 C2
B2
B1
D1
D2
20o Circle
10o Circle
 
(a) 
 
(b) 
Figure 2.4  Tablet positions in the OPI system and standard system: (a) top view of the 
bottom of the dissolution vessel with nine different tablet positions in the OPI system, (b) 
the front view of the dissolution vessel with three different tablet positions (0°,10°, 20°) 
in the standard system. 
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Figure 2.6Calibrationcurve for aspirin 
. 
Table 2.2  Calibration Data for Aspirin 
Absorption 1 Absorption 2 Absorption 3 Average Concentration(mg/mL) 
0 0 0 0 0 
0.2885 0.2887 0.2883 0.2885 0.1 
0.579 0.576 0.576 0.577 0.2 
0.866 0.869 0.86 0.865 0.3 
1.151 1.157 1.155 1.154 0.4 
1.441 1.443 1.442 1.442 0.5 
2.165 2.161 2.163 2.163 0.75 
2.844 2.845 2.837 2.842 1 
  
y = 0.3512x - 0.004 
R² = 0.9999 
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2.4 Data Processing 
 
The dissolution profiles are presented in terms of drug release fraction (mD/mT), that is, 
the mass of released drug in the dissolution medium at any time t out of the total mass of 
drug initially in the tablet, as a function of time. The absorbance data obtained from the 
UV spectrophotometer was first converted to aspirin concentration at given time, (Cj, in 
mg/mL), and then transformed into drug mass release fraction (mD/mT) using the 
following equations, in order to account for the drug mass removed with each sample:   
 
 1 1 1
*
D
T
m t C
for j
m C
 (2.1) 
 
 
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
1
1
1 1 2
*
j
D j j
k
kT
m t C V V
j C for j n
m C V V
 (2.2) 
where j is an index identifying the number of sampling (j=1, 2, … 8), mD(tj) is the mass 
of released salicylic acid at time tj, mTis the total mass of salicylic acid initially in the 
tablet, Cj is the dissolved aspirin concentration in the j
th
 sampling at time tj, C* is the 
concentration of aspirin when the tablet is fully dissolved in 500 mL dissolution medium, 
ΔV is each sampling volume (10 mL) and V is the initial volume of dissolution medium 
(500 mL). At the beginning of the experiment(t=t1=5 minutes) the first sample was taken 
(j=1) resulting in an initial concentration C1, and the 8
th
 sample was taken at t8=60 
minutes (j=8).  
The dissolution profiles obtained with tablets at each position in the testing 
system were compared to those from its paired standard system in order to determine 
whether these dissolution curves were statistically similar or not.  Two approaches were 
used.  The first approach was that recommended by the FDA to quantify the 
  
26 
 
similarity/difference of two dissolution profiles. This approach consists of a model-
independent method based on the difference factor (f1) and similarity factor (f2):  
 



 


1
1
1
100
n
t t
t
n
t
t
R T
f
R
 (2.3) 


    2 0.52 10
1
1
50log {[1 ( ) ( ) ] 100}
n
t t
t
f R T
n
 (2.4) 
where Rtis the reference assay at time t (i.e., the results from the standard system),Τtis the 
test assay at the same time (i.e., the paired results from the testing system), and n is the 
number of time points. The difference factor(f1) calculates the percent (%) difference 
between the two curves at each time point and measures the relative error between two 
curves. The higher the f1(which can be in the range of 0 to 100), the higher the average 
difference between reference and test curves is (Moore and Flanner, 1996). The similarity 
factor (f2) is a logarithmic reciprocal square root transformation of the sum-squared error 
of differences between the reference and test profiles over all time points (which can be 
in the range -α to 100).  The higher the f2, the lower the average difference between 
reference and test curves is (Costa and Lobo, 2001). Public standards have been set by 
FDA for f1and f2 factors. Accordingly, statistical similarity between the two curves being 
compared requires that 0<f1<15 or 50<f2<100(FDA, 1997). 
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CHAPTER 3 
RESULTS 
 
The drug release profile of aspirin tablets compressed at different pressures used regular 
dissolution method in the standard USP Dissolution Testing Apparatus 2. Then the drug 
release profile of aspirin tablets with different pressures used regular dissolution method 
in the OPI system. The dissolution profile of aspirin tablet with different pressures at 
three different tablet locations (0°, 10° and 20°) in the Standard USP Dissolution Testing 
Apparatus 2 (Standard System) were obtained third as per USP method. The forth is the 
drug release profile of aspirin tablet with different pressures at nine different tablets 
locations was obtained for the Modified System as per the method described in the 
previous chapter. The results were interpreted by potting mD/mT (%)(drug release) against 
time (min) and by calculating similarity factor (f1) and difference factor (f2). 
 
3.1Results for Dissolution Tests in the Standard USP Dissolution Testing Apparatus 
by Dropping Tablets into Medium Using Testing Method #1 
 
In the Standard USP Dissolution System, the dissolution profiles for aspirin tablet were 
obtained by dropping into the dissolution vessel under an agitation speed of 50 rpm. The 
results are reported here in terms of drug release ratiomD/mT(%). Figure 3.1 presents these 
results. 
Based on the USP specifications for the Aspirin tablets used in this work, each 
individual run should produce a dissolved amount of aspirin no less than 80% (Q) of the 
labeled amount of C9H8O4 contained in the tablet (360 mg) when sampling at 30 
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minutes. This is the case here for the centrally located tablet, since the experimentally 
obtained fractions at 30 minutes were found to be 87.49%, implying that the equipment 
was suited to conduct dissolution testing with aspirin tablets. 
A noticeable difference of dissolution profiles between different tablets 
compression pressures was found through the figure 3.2. Three curves started at the same 
mass at the beginning, butthey diverged with time depending on the tablet with different 
compression pressure.The dissolution curve for the commercial tablet began atmD/mT = 0, 
and then increased fast, reaching mD/mT = 68% at10th min. After 10 min, a lowerrelease 
rate of Commercial tablets was observed.from45min, the release rate of commercial 
tablets almost kept constant. For tablets with 1000-pound compression pressure, its 
dissolution profile was extremely similar to the commercial tablets, figure 3.1 showed the 
tendency of the similarity. According to Table 3.1, f1and f2 values of the 1000-pound 
tablets reached 2.97 and 75.90 respectively, indicating the similarity between commercial 
tablets and 1000-pound tablets. For tablets with compression pressure of 2000 pound and 
3000 pound, a significant difference was found in the figure 3.1, especially for the 3000-
pound tablets. At t =5min, the dissolution curves were foundto be much lower than the 
dissolution curve of commercial tablets, only reaching mD/mT = 50%. After 5 min, the 
dissolutionrates increased slightlyrespect to time. At t=60 min, mD/mT value of 3000 
pound tablets was 10% lower than the mD/mT value of commercial tablets. Respectively, 
the f1and f2 values of the 2000-pound tablets were 5.65, 65.3, and f1and f2 values of the 
3000-pound tablets were over 10 and lower than 56.Based on the f1and f2 values listed 
above (table. 3.1), the difference between the dissolution profiles for aspirin tablets with 
different compression pressure in the standard system could be easily recognized. 
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Although f1and f2 values fortablets with pressure of 2000 pound and 3000 pound were 
within FDA range, the difference still existed, which verified the existence of the 
difference produced by different tablets compression pressure.  
In addition, f1 and f2 values reported in Table 3.1 implied that tablets with the 
pressure of 1000 pound, 2000 poundand 3000 pound would have different dissolution 
profiles despite a certain degree of similarity was shown. These results confirm that the 
dissolution profiles of aspirin tablets depend on the compression pressure. 
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Figure 3.1Dissolution profiles of aspirin tablets with different pressures in standard 
system by dropping tablets into medium using testing method #1. 
 
 
 
Table 3.1f1 and f2 Value of Tablets with Different Pressure in Standard System by 
Dropping Tablets into Medium Using Testing Method #1. 
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Tablets with 1000 pound pressure 2.97 75.70 
Tablets with 2000 pound pressure 5.66 65.29 
Tablets with 3000 pound pressure 10.39 55.07 
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3.2Results for Dissolution Testsin the OPI Systemby Dropping Tablets into Medium 
Using Testing Method #1 
 
The dissolution difference between pressures were tested in standard system by USP 
method, the similar dissolution profiles in the standard system were found in OPI system,  
which indicated the sensitivity of the OPI system can be verified.  
f1 and f2 methods were used to identify the similarity/difference between aspirin 
tablets with different pressures in OPI system. Meanwhile, f1 and f2 methods were used to 
analyze the dissolution data of tablets with same pressure in two systemsin order to 
compare the tablets dissolution profiles with same pressure under standard system and 
OPI system. 
A difference between different pressures was also foundin OPI system through 
the figure 3.2.1. The corresponding f1 and f2 values quantifying the similarity/difference 
of the dissolution profiles with different pressures are presented in the Table 3.2.1. In this 
case, f1 was foundto be in the range 2.3–10.0, stating a relatively small differencebetween 
the release profiles at different compression pressures and the reference release 
profile(standard tablets); f2values in this part were found to be in therange 55.2–
78.8,indicating that the release profiles were statisticallysimilar to the reference release 
profile, however as previous experiment, f1 value of tablets with 3000 pound pressure 
was 10.41, which was much higher than the f1 of tablets with 1000 pound, that is 2.3, and 
2000 pound, that is 4.9. The comparison between standard system and OPI system in 
each particular tablet pressure were shown in Figure 3.2.2-3.2.5. According to f1 and f2 
values in table 3.2.2-3.2.5, one fact can be seen that f1 and f2 values between experiments 
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operated under standard system and experiments operated under OPI system were 
corresponding, indicating that like standard system, OPI system was sensitive enough to 
detect differences of the tablets. 
The comparison between tablets with each compression pressure was conducted 
in this section. f1 and f2 values of tablets with every compression pressure between OPI 
and standard system were shown Table 3.2.2-3.2.5. Through the Figure 3.2.2-3.2.5, and 
the Table 3.2.2-3.2.5, curves of tablets dissolution profiles were highly corresponding.  
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Figure 3.2.1Dissolution profiles of aspirin tablets with different pressures in OPI system 
by dropping tablets into medium using testing method #1. 
 
Table 3.2.1f1 and f2 Value of Tablets with Different Pressure by Dropping Tablets into 
Medium Using Testing Method #1. 
Tablet Location f1 (Similarity factor) f2 (Difference factor) 
Standard Tablets   
Tablets with 1000 pound pressure 2.29 78.78 
Tablets with 2000 pound pressure 4.96 69.05 
Tablets with 3000 pound pressure 10.02 55.28 
 
0
10
20
30
40
50
60
70
80
90
100
0 10 20 30 40 50 60 70
m
D
/m
T 
(%
) 
t (min) 
Dropped Tablets in OPI System 
Commercial Tablets
1000-Pound Tablets
2000-Pound Tablets
3000-Pound Tablets
  
34 
 
Figure 3.2.2 Comparison of dissolution profiles of aspirin commercial tablets in standard 
system and OPI system by dropping tablets into medium using testing method #1. 
 
 
Table 3.2.2f1 and f2 Values of Aspirin Commercial Tablets In OPI System by Dropping 
Tablets into Medium Using Testing Method #1. 
Tablet Location f1 (Similarity 
factor) 
f2 (Difference 
factor) 
Dropped commercial tablets in standard system   
Dropped commercial tablets in OPI system 3.46 75.48 
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Figure 3.2.3Comparison of dissolution profiles of aspirin 1000-pound tablets in standard 
system and OPI system by dropping tablets into medium using testing method #1. 
 
 
Table 3.2.3f1 and f2 Values of Aspirin 1000-Pound Tablets In OPI System by Dropping 
Tablets into Medium Using Testing Method #1. 
Tablet Location f1 (Similarity 
factor) 
f2 (Difference 
factor) 
Dropped 1000-pound tablets in standard system   
Dropped 1000-pound tablets in OPI system 2.44 80.12 
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Figure 3.2.4Comparison of dissolution profiles of aspirin 2000-pound tablets in standard 
system and OPI system by dropping tablets into medium using testing method #1. 
 
  
Table 3.2.4f1 and f2 Values of Aspirin 2000-Pound Tablets In OPI System by Dropping 
Tablets into Medium Using Testing Method #1. 
Tablet Location f1 (Similarity 
factor) 
f2 (Difference 
factor) 
Dropped 2000-pound tablets in standard system   
Dropped 2000-pound tablets in OPI system 4.06 72.17 
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Figure 3.2.5Comparison of dissolution profiles of aspirin 3000-pound tablets in standard 
system and OPI system by dropping tablets into medium using testing method #1. 
 
 
Table 3.2.5f1 and f2 Values of Aspirin 3000-Pound Tablets In OPI System by Dropping 
Tablets into Medium Using Testing Method #1. 
Tablet Location f1 (Similarity 
factor) 
f2 (Difference 
factor) 
Dropped 3000-pound tablets in standard system   
Dropped 3000-pound tablets in OPI system 3.84 75.33 
 
 
3.3Results for Tablets at Three Positions in the Standard USP Dissolution 
TestingApparatus 2 Using Testing Method #2 
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There are various factors that affect the drug release profile in USP Dissolution 
Apparatus 2. A number of studies related to the location of tablet and impeller, presence 
of baffles, geometric effects of the vessel, and even vibration effects ondrug dissolution 
rate have been carried on.The position may vary from time to time when the tablet 
reaches the vessel bottom. Therefore, tablet location has a major effect, and that 
statistically significant differences exist in the dissolution profiles between centrally 
located tablets and tablets positioned off-centered. 
In the Standard USP Dissolution System, the dissolution profiles for aspirin tablet 
was obtained at three different tablet locations (0°, 10°, 20°) on the bottom of the 
dissolution vessel under an agitation speed of 50 rpm. Figure 3.4.1-3.4.4 presentthese 
results.  
There was a significant difference between all three dissolution profiles at three 
different tablet positions.As the data showed in figure 3.3.1, the fact was foundthe greater 
the distance from the central location,the higher the dissolution rate. In the figure 3.3.1, 
the dissolution curve of tablets in central position was similar to the dissolution curve for 
tablets dropped into the medium using method #1. With the increasing of the deviation of 
the distance to the centerline, the dissolution rate of the tablets increased obviously. The 
corresponding f1 and f2 values quantifying the similarity/difference of the dissolution 
profiles with respect to that for the centrally located tablet are presented in the Table 
3.4.1. Even thoughf1 and f2 are in the required range to insure statistical similarity, f1 of 
tablets at 20° locations is much higher than the value of tablets at 10°locations, which 
imply that the dissolution profile difference exists. These results confirm that the 
dissolution profiles of the aspirin tablets depend strongly on the tablet location in the 
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dissolution vessel for the Standard System.These results are in agreement with previously 
reported work from this and other research groups. 
 
Figure 3.3.1Dissolution profiles of commercial tablets at 3 positions in standard system 
 
Table 3.3.1f1 and f2 Value of Commercial Tablets at 3 Positions in Standard System 
Tablet Location f1 (Similarity factor) f2 (Difference factor) 
Tablets using official method   
Tablets at center 3.06 80.20 
Tablets at 10° off-center 8.63 59.99 
Tablets at20° off-center 10.67 55.64 
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Figure 3.3.2 Dissolution profiles of 1000-pound tablets at 3 positions in standard system 
 
Table 3.3.2f1 and f2 Value of 1000-Pound Tablets at 3 positions in Standard System 
Tablet Location f1 (Similarity factor) f2 (Difference factor) 
Tablets using official method   
Tablets at center 1.35 91.68 
Tablets at 10° off-center 3.46 77.57 
Tablets at20° off-center 7.97 60.59 
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Figure 3.3.3 Dissolution profiles of 2000-pound tablets at 3 positions in standard system 
 
Table 3.3.3f1 and f2 Value of 2000-Pound Tablets at 3 positions in Standard System 
Tablet Location f1 (Similarity factor) f2 (Difference factor) 
Tablets using official method   
Tablets at center 0.22 99.25 
Tablets at 10° off-center 3.80 76.44 
Tablets at20° off-center 8.18 61.27 
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Figure 3.3.4 Dissolution profiles of 3000-pound tablets at 3 positions in standard system 
 
Table 3.3.4f1 and f2 Value of 3000-Pound Tablets at 3 positions in Standard System 
Tablet Location f1 (Similarity factor) f2 (Difference factor) 
Tablets using official method   
Tablets at center 0.24 99.55 
Tablets at 10° off-center 5.69 70.50 
Tablets at20° off-center 10.22 58.41 
 
 
3.4Results for the Tablets at Nine Positions in OPI System Using Testing Method #2 
 
In all dissolution tests with the modified system, the aspirin tablets remained at their 
initial location for the entire duration of the experiment. Since the tablets did not 
0
10
20
30
40
50
60
70
80
90
100
0 10 20 30 40 50 60 70
m
D
/m
T 
(%
) 
t (min) 
3000-Pound Tablets  in Standard System  
Dropped Tablets
Tablets in Central Position
Tablets in 10° off-center
Tablets in 20° off-center
  
43 
 
disintegrate, the dissolution process was driven by erosion. In order to compare the 
profiles of off-center tablets with centrally located tablets, the similarity values f1 and 
difference values f2 were used. Table 3.4.1-3.4.4 shows the f1 and f2 valuesof off-center 
dissolution profiles comparing with the dissolution profile of the centrally located tablets. 
In all cases, when compared to the dissolution profiles in OPI system by dropping 
in this case,f1 values were in the range 2-4, much lower than the upper limit required by 
FDA for similarity (15), and f2 values were in the range and more than 75, within the 
FDA range 50-100. Thus, all values were within the acceptance level. Indicating off-
center dissolution profiles were statistically similar to the baseline profile obtained from 
centrally located tablets in the modified USP Dissolution Apparatus 2 and the OPI system 
can avoid the interferes from tablets initial location.. As shown in Figure below, one can 
easily see the OPI system is robust enough.   
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Figure 3.4.1  Dissolution profiles of commercial tablets at 9 positions in OPI system 
 
Table 3.4.1f1 and f2 Value of Commercial Tabletsat 9 Positions in OPI System  
Tablet Location f1 (Similarity factor) f2 (Difference factor) 
Dropped tablets   
Tablets at position O 2.64 81.03 
Tablets atposition A1 3.36 76.63 
Tablets atposition B1 3.41 76.04 
Tablets atposition C1 3.56 74.71 
Tablets atposition D1 3.16 76.85 
Tablets atposition A2 3.23 77.21 
Tablets atposition B2 2.95 78.81 
Tablets atposition C2 2.76 80.57 
Tablets atposition D2 2.48 81.87 
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Figure 3.4.2Dissolution profiles of 1000-pound tablets at 9 positions in OPI system 
 
Table 3.4.2f1 and f2 Value of 1000-Pound Tablets at 9 Positionsin OPI System 
Tablet Location f1 (Similarity factor) f2 (Difference factor) 
Dropped tablets   
Tablets at position O 2.59 80.24 
Tablets atposition A1 3.07 77.72 
Tablets atposition B1 1.83 86.84 
Tablets atposition C1 2.50 82.02 
Tablets atposition D1 2.95 79.52 
Tablets atposition A2 2.29 83.59 
Tablets atposition B2 2.20 84.24 
Tablets atposition C2 2.51 82.69 
Tablets atposition D2 2.49 82.49 
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Figure 3.4.3Dissolution profiles of 2000-pound tablets at 9 positions in OPI system 
 
Table 3.4.3f1 and f2 Value of 2000-Pound Tablets at 9 Positionsin OPI System 
Tablet Location f1 (Similarity factor) f2 (Difference factor) 
Dropped tablets   
Tablets at position O 2.94 80.65 
Tablets atposition A1 2.87 80.84 
Tablets atposition B1 3.55 76.61 
Tablets atposition C1 2.42 83.02 
Tablets atposition D1 3.13 79.24 
Tablets atposition A2 1.97 85.64 
Tablets atposition B2 3.73 76.63 
Tablets atposition C2 3.78 75.82 
Tablets atposition D2 2.62 81.79 
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Figure 3.4.4Dissolution profiles of 3000-pound tablets at 9 positions in OPI system 
 
Table 3.4.4f1 and f2 Value of 3000-Pound Tablets at 9 Positionsin OPI System  
Tablet Location f1 (Similarity factor) f2 (Difference factor) 
Dropped tablets   
Tablets at position O 3.03 79.43 
Tablets atposition A1 3.51 77.36 
Tablets atposition B1 3.27 78.29 
Tablets atposition C1 2.61 81.83 
Tablets atposition D1 3.58 77.76 
Tablets atposition A2 3.55 76.71 
Tablets atposition B2 3.31 78.85 
Tablets atposition C2 3.03 79.72 
Tablets atposition D2 3.91 75.65 
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CHAPTER 4 
DISCUSSION 
 
 
In previous work
16-18
, OPI system was found more robust than the standard USP method. 
In order to determine OPI is also sensitive enough to detect the difference as USP 
standard method does under the change of experimental condition, further experiments 
were conducted. Due to the fact that tablets with different pressures might have different 
dissolution profile, the pressure difference was selected as the variable in the test. 
According to USP specification, USP method in Apparatus 2 was used firstly to see 
whether the difference of dissolution profiles exists under different aspirin tablets with 
different pressures. Results showed that tablets with different pressures had different 
dissolution curves. If the similar results concluded by OPI system, the sensibility of the 
OPI system can be verified.  
A difference between different pressures was found in both systems through the 
figure. f1values was foundto be in the range 2.0–11.0 and f2values in this part were found 
to be in therange 55.0–79.0 in both systems. f1 values of tablets with 1000 pound, 2000 
pound and 3000 pound in standard system were 2.9, 5.7 10.4 respectively, meanwhile, in 
Table 3.2.1,f1values of tablets dissolution profiles in OPI system using testing method#1 
were 2.3, 4.9 and 10.0; on the other hand, f2values of both systems were corresponding as 
well. f1and f2values of tablets with specific pressure were shown in the Table 3.2.2-3.2.5, 
indicating in OPI system, dissolution profiles of tablets with different pressures were 
extremely similar, that is, just like standard system; OPI system was sensitive enough to 
detect differences of the tablets.  
In the following experiments, significant difference in dissolution performance 
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can be seen between off-center and centered tablets in the Standard System. A small 
tablet off-center displacement of only 10° is already capable of producing significantly 
and statistically different dissolution results, with f1 value of 8.63, more than f1value of 
central tablets, 3.05 when compared to the curves of dropped tablets as reference curve. 
When the displacement reaches 20° off-center, f1 value turns to be 10.67, indicating that 
greater deviation of the tablet location from the centerline can produce larger deviation in 
dissolution profiles.  
Distance effect did not exist in the OPISystem. Greater deviations of the tablet 
location from the centerline hadsimilar results as the central location tablets in the 
dissolution profiles, which is different to the Standard System. As shown in Table 3.4.1-
3.4.4. That is,all the deviations are within the acceptable range guided by FDA. Thus, 
tablet locations in the bottom of the vessel are not that important in the OPI System. In 
typical dissolution tests, the OPI testing apparatus is robust enough to produce similar 
dissolution profiles even the tablet is freely dropped into the testing vessel at 50 rpm 
agitation speed. 
According to previous work, the reason for this improvement resides in the 
deliberateremoval of the symmetry, obtained by positioningthe impeller off center with 
respect to thevessel, as proposed here for the OPI system. In theStandard System, the 
symmetric position of the impellergenerates a poorly mixed region just belowthe 
impeller,precisely where the tablet is usuallylocated 
In sum, the results of this work confirm that dissolution of aspirin tablets 
issignificantly affected by the exact location of the dissolvingtablet, as also described in 
previous work.However, and more importantly, this work additionallyshows that OPI 
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system can obviate to this problem and resultin amuchmore robust dissolution testing 
system. On the other hand, a good sensibility to the difference of the tablets showed in 
the work, indicating the OPI system is sensitive enough to analyze the tablets while it has 
a strong independence to the effect factors such as the deviation of the tablet location 
from the centerline.In addition, the OPI system is expectedto require very low capital 
investment for its commercialimplementation and minimal retraining ofpersonnel, while 
providing a much more robust testthat is insensitive to tablet location and, most likely,to 
other small geometric imperfections in the equipmentand to small operator-dependent 
variations inthe test procedure. 
 
 
 
  
  
51 
 
CHAPTER 5  
CONCLUSIONS 
 
 
The following conclusions can be drawn from this work: 
1. Dissolution tests conducted using aspirin tablets with different compression pressures 
in the standard USPDissolution Testing Apparatus2 resulted in dissolution curves that 
werenot statistically similar(using both f1 and f2) respectiveof the tablets pressures, 
indicating that tablets pressure in this particular case is one of the variables, which 
causes the different dissolution profiles and can be detected in the standard 
USPDissolution Testing Apparatus2. 
 
2. By contrast, similar tests conducted usingthe standard USPDissolution Testing 
Apparatus2 resulted in dissolution curves that werealso statistically similar just as the 
former case. Additionally, f1 and f2 of each curve was corresponding, stating that the 
OPI system was sensitive enough to detect the slice difference between tablets as 
standard USPDissolution Testing Apparatus2 did. 
 
3. In this work the dissolution performance of aspirin tablets with different pressures in 
the Standard Dissolution System where the impeller is placed centrally and 
symmetrically with respect to the unbaffled hemispherical-bottom vessel of the USP 
Dissolution Testing Apparatus 2 is strongly dependent on tablet position, as 
previously reported by this and other research groups.  Thus, this apparatus is prone 
to highly variable results which may not be associated with the tablets undergoing 
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testing but with hydrodynamic characteristics of the apparatus itself and the location 
of the tablet on the vessel bottom. 
 
4. OPI system of the USP Dissolution Testing Apparatus 2 in which the impeller was 
placed off-center by 8 mm was proposed, and a prototype was assembled, and tested 
in this work. This OPI system generated dissolution profiles for aspirin tablets that 
were nearly completely insensitive to tablet location. And when compared to the 
results in OPI system by dropping the tablets, similarity of the results can be easily 
seen, which states OPI system is not only sensitive enough to detect the slice 
experimental condition differences, but also much more robust than the Standard 
Dissolution System. 
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Appendix A 
DERVIATION OF EQUATION 2.1 
 
In this appendix, Equation 2.1 in Section 2.4 was derived based on the mass balance inthe 
dissolution system. 
 
Thedrug release ratio needed to be determined: 
 
 
 
i.e., the amount of drug in solution at any time t out of the total initial amount ofdrug in 
the tablet. 
The initial volume of solution (medium) is V, and each sample has a volumeequal to V. 
Also, the mass of drug initially in the tablet is: 
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In general, at any time t just after taking a sample, the mass balance for the drugremoved 
from the tablet (and transferred to the solution) gives: 
 
 
In our system, the tablet was dropped in the medium at t=to, the agitation wasimmediately 
started, and a sample was taken (at t=t1=5 min).: 
 
 
For t=t1 (corresponding to a sample concentration C=C1) the mass balance gives: 
 
For t=t2 (corresponding to a sample concentration C=C2): 
 
For t=ti(corresponding to a sample concentration C=Ci): 
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For t=tn(corresponding to a sample concentration C=Cn): 
 
Hence, for t=tn(corresponding to a sample concentration C=Cn): 
 
and finally: 
 
Remark: in this study first sample was taken at t=t1=5 min. Thismeans that the 9h sample 
corresponds to n=9, i.e.,n= 1, 2, 3, 4, 5, 6, 7 and 8(9 samples taken every 5 minutes, 
starting at time t=t1=5min, and ending at time t8=60 minutes). 
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Appendix B 
 
DISSOLUTION OF TABLETS WITH DIFFERENT COMPRESSION 
PRESSURES AT EACH POSITION OF NINE POSITIONS IN OPI SYSTEM 
In this appendix, dissolution profiles of aspirin tablets in are plotted as concentration ratio 
mD/mT (%) vs. time in Figure B.1 to B.9. 
 
 
Figure B.1Dissolution profiles of tablets with different pressures at position Oin OPI 
system. 
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Figure B.2 Dissolution profiles of tablets with different pressures at position A1 in OPI 
system. 
 
 
Figure B.3 Dissolution profiles of tablets with different pressures at position B1 in OPI 
system. 
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Figure B.4 Dissolution profiles of tablets with different pressures at position C1 in OPI 
system. 
 
 
Figure B.5 Dissolution profiles of tablets with different pressures at position D1 in OPI 
system. 
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Figure B.6 Dissolution profiles of tablets with different pressures at position A2 in OPI 
system. 
 
 
Figure B.7 Dissolution profiles of tablets with different pressures at position B2 in OPI 
system. 
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Figure B.8 Dissolution profiles of tablets with different pressures at position C2 in OPI 
system. 
 
 
Figure B.9 Dissolution profiles of tablets with different pressures at position D2 in OPI 
system. 
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